CVR 26688949Public limited company (A/S)Engroshandel med medicinalvarer og sygeplejeartikler (464610)København SFounded 5 Jul 2002
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about UCB NORDIC A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
48
CVR, Aug 2026
+1 (+2.1%) over 12 months
Gross profit
88.3M
DKK, annual report 2025
Result
+6M
DKK, annual report 2025
Equity
18M
DKK, annual report 2025
UCB Pharma SA100% of capital and votes, since 20 Nov 2020
Operating company
Dandex estimate: 48 employees registered in 2026Mari-Ann Retzsince 1 Jun 2022
100% of capital and votessince 20 Nov 2020
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
100% of capital and votes29 Mar 2012 to 20 Nov 2020
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report a calibrated decision model reading the auditor's text, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
1 Jun 2022 to 13 Nov 2026.
9 Sep 2002 to 13 Nov 2026. Showing 25 of 27. The list above has every one.
Aug 2026, monthly: 48 employees, 44 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 6 | 8 | 24 | 32 | 39 | 31 | 26 | No count | No count | No count | No count | 22 | 21 | 27 | 27 | 28 | 28 | 31 | 30 | 30 | 31 | 31 | 27 | 31 | 29 | 29 | 30 | 29 | 28 | 28 | 28 | 28 | 26 | 25 | 26 | 26 | 27 | 24 | 24 | 25 | 25 | 24 | 24 | 23 | 24 | 23 | 24 | 23 | 25 | 24 | 27 | 27 | 28 | 28 | 28 | 27 | 27 | 24 | 24 | 25 | 25 | 25 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 27 | 27 | 26 | 25 | 27 | 28 | 30 | 30 | 34 | 34 | 36 | 35 | 35 | 37 | 39 | 41 | 41 | 41 | 42 | 43 | 42 | 42 | 40 | 42 | 42 | 40 | 39 | 39 | 42 | 41 | 41 | 42 | 40 | 40 | 42 | 42 | 42 | 42 | 42 | 43 | 43 | 43 | 44 | 43 | 43 | 43 | 41 | 42 | 42 | 44 | 44 | 44 | 45 | 45 | 45 | 45 | 44 | 45 | 45 | 45 | 45 | 44 | 44 | 45 | 46 | 47 | 46 | 44 | 45 | 45 | 47 | 48 | 47 | 47 | 46 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 |
| FTE | 1 | 4 | 5 | 19 | 36 | 42 | 44 | 36 | 33 | 31 | 30 | 29 | 29 | 26 | 26 | 26 | 26 | 26 | 28 | 27 | 27 | 28 | 28 | 25 | 28 | 26 | 26 | 27 | 26 | 26 | 26 | 26 | 26 | 24 | 23 | 24 | 25 | 26 | 24 | 24 | 25 | 25 | 24 | 23 | 23 | 23 | 23 | 24 | 23 | 23 | 23 | 25 | 25 | 27 | 26 | 26 | 26 | 24 | 22 | 23 | 24 | 23 | 23 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 24 | 26 | 25 | 24 | 26 | 27 | 28 | 29 | 33 | 33 | 35 | 34 | 34 | 36 | 37 | 40 | 39 | 39 | 41 | 41 | 40 | 41 | 40 | 40 | 40 | 39 | 38 | 38 | 40 | 40 | 40 | 41 | 39 | 39 | 41 | 40 | 40 | 40 | 41 | 40 | 42 | 42 | 43 | 42 | 41 | 40 | 39 | 40 | 41 | 43 | 44 | 42 | 44 | 44 | 44 | 43 | 43 | 44 | 44 | 44 | 42 | 43 | 43 | 44 | 44 | 45 | 44 | 42 | 43 | 43 | 43 | 46 | 45 | 45 | 44 | 46 | 46 | 46 | 46 | 46 | 45 | 46 | 44 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Annual 2002 to 2009 and 2011 to 2014; quarterly Q1 2010 to Q4 2010; monthly Jan 2015 to Aug 2026.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 60,527 | Not reported | Not reported | Not reported | 88,278 |
| Operating profit | +4,032 | +5,333 | +5,564 | +7,376 | +8,643 |
| Result for the year | +3,016 | +4,004 | +3,888 | +5,226 | +6,014 |
| Equity | 14,114 | 15,118 | 16,106 | 17,333 | 18,047 |
| Total assets | 59,202 | 57,654 | 65,918 | 79,081 | 98,198 |
| Employees (average) | 40 | 40 | 42 | 43 | 44 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | 31% | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | 4.1% |
| EBITDA | 4,093 | 5,379 | 5,569 | 7,376 | Not reportednote 2 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 29% | 0% | 5% | 2.4% | 2.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 0note 3 | 0note 3 | Not reportednote 4 | Not reportednote 4 | 0note 3 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 8 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 17 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 10 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 29 Jun 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 28 Jun 2022
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For UCB NORDIC A/S, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
Merger (fusion), as the continuing company (fortsættende selskab)
From CVR, read 13 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 13 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
35 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Bestyrelse:
Fratrådte:
Afshin Risseh, den 08.01.2025.
Bestyrelse:
Fratrådte:
Ana Isabel Infante Gonzalez De La Aleja, (formand), den 08.01.2025, Per Ove Jonas Berg, den 08.01.2025.
Tiltrådte:
Christina Dyreborg Jeppesen, den 08.01.2025, Jaana Mattila, den 08.01.2025, Laura Ann Byram, (formand), den 08.01.2025.
Direktion:
Fratrådte:
Henrik Dramer Bøgebjerg Hansen, den 01.06.2022.
Tiltrådte:
Mari-Ann Retz, den 01.06.2022.
Bestyrelse:
Fratrådte:
Ilaria Villa, (formand), den 20.05.2022.
Tiltrådte:
Ana Isabel Infante Gonzalez De La Aleja, (formand), den 20.05.2022.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 13.07.2021.
Tiltrådte:
CVR-NR. 31061741 MAZARS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Midtermolen 1, 2. tv, 2100 København Ø, den 13.07.2021.
Bestyrelse:
Fratrådte:
Willy Constant Cnops, (formand), den 04.12.2019.
Tiltrådte:
Ilaria Villa, (formand), den 04.12.2019.
Bestyrelse:
Fratrådte:
Francois Joseph Gérald Vanier, den 13.05.2019.
Tiltrådte:
Afshin Risseh, den 13.05.2019.
Bestyrelse:
Fratrådte:
Yogesh Naranbhai Khatri, den 15.01.2018.
Tiltrådte:
Francois Joseph Gérald Vanier, den 15.01.2018.
Ny adresse: Edvard Thomsens Vej 14, 7., 2300 København S
Vedtægter ændret: 01.12.2016
Bestyrelse:
Fratrådte:
.
Direktion:
Fratrådte:
Arnaud Lefèvre (adm. dir), den 01.12.2016.
Tiltrådte:
Henrik Dramer Bøgebjerg Hansen, den 01.12.2016.
Selskabet tegnes af en direktør eller af den samlede bestyrelse..
Bestyrelse:
Fratrådte:
Flemming Erik Allan Andersen, den 02.05.2016.
Tiltrådte:
Arnaud Lefèvre, den 02.05.2016.
Direktion:
Fratrådte:
Flemming Erik Allan Andersen (adm. dir), den 02.05.2016.
Tiltrådte:
Arnaud Lefèvre (adm. dir), den 02.05.2016.
Bestyrelse:
Fratrådte:
Mohammed Nazir Khoso Baluch (formand), den 01.12.2015.
Tiltrådte:
Willy Constant Cnops (formand), den 04.02.2016.
CVR-nummer:
26688949.
NAVN:
UCB NORDIC A/S.
Adresse: Arne Jacobsens Allé 15, 2300 København S.
Kommune: København.
Bestyrelse:
Fratrådte:
Frantisek Rozdalovsky, den 18.06.2015.
Tiltrådte:
Yogesh Naranbhai Khatri, den 18.06.2015.
Bestyrelse:
Udtrådt af bestyrelsen:
Philippe Edgar R Vandeput, den 31.05.2014, Jean-Luc Pierre Raymond Moreau, den 31.05.2014.
Indtrådt i bestyrelsen:
Mohammed Nazir Khoso Baluch (formand), den 31.05.2014, Frantisek Rozdalovsky, den 31.05.2014.
Bestyrelse:
Udtrådt af bestyrelsen:
Scott Dunseth Myers, den 28.02.2012, Dominique Laurent Vanfleteren, den 28.02.2012.
Indtrådt i bestyrelsen:
Philippe Edgar R Vandeput (formand), den 28.02.2012, Jean-Luc Pierre Raymond Moreau, den 28.02.2012.
Vedtægter ændret:
15.07.2009.
Nyt binavn: SCHWARZ PHARMA A/S (UCB NORDIC A/S).
Kapitalforhøjelse:
kr. 150.000,00 indbetalt ved fusion, kurs 706,91.
Kapitalen udgør herefter kr. 850.000,00.
Selskabet er fusioneret med CVR-NR. 29137676 SCHWARZ PHARMA ApS, der samtidig er opløst.
Erhvervs- og Selskabsstyrelsen har modtaget
fusionsplan i henhold til aktieselskabslovens § 134 a og
anpartsselskabslovens § 65 for fusion mellem
CVR-NR. 26688949 UCB NORDIC A/S (fortsættende).
CVR-NR. 29137676 SCHWARZ PHARMA ApS (ophørende).
Endvidere er modtaget erklæring fra
vurderingsmændene om kreditorernes retsstilling jf.
aktieselskabslovens § 134 c, stk. 4 og
anpartsselskabslovens § 65.
Bestyrelse:
Udtrådt af bestyrelsen:
Els Hendrickx, den 19.02.2009.
Indtrådt i bestyrelsen:
Dominique Laurent Vanfleteren, den 19.02.2009.
Vedtægter ændret:
23.12.2008.
Kapitalforhøjelse:
kr. 100.000,00 indbetalt kontant, kurs 35.000,00.
Kapitalen udgør herefter kr. 700.000,00.
Bestyrelse:
Udtrådt af bestyrelsen:
Giles David Moss, den 23.04.2008, Guido Irena Joannes Coleta Van Dingenen, den 23.04.2008.
Indtrådt i bestyrelsen:
Scott Dunseth Myers (formand), den 23.04.2008, Els Hendrickx (Grotenberge), den 23.04.2008.
Bestyrelse:
Udtrådt af bestyrelsen:
Luc René Benoît Vermeesch, den 22.05.2006, Jørgen Damsbo Andersen, den 22.05.2006.
Indtrådt i bestyrelsen:
Giles David Moss (formand), den 22.05.2006, Adm. direktør Flemming Erik Allan Andersen, den 22.05.2006.
Direktion:
Udtrådt af direktionen:
Jørgen Damsbo Andersen, den 22.05.2006.
Indtrådt i direktionen:
Adm. direktør Flemming Erik Allan Andersen (adm. dir), den 22.05.2006.
Vedtægter ændret:
30.12.2005.
Kapitalforhøjelse:
kr. 100.000,00 indbetalt kontant, kurs 10.000,00.
Kapitalen udgør herefter kr. 600.000,00.
Vedtægter ændret:
31.05.2005.
Kapitalforhøjelse:
kr. 375.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00.
Selskabet er omdannet til et A/S med CVR-nr 26688949.
NAVN: UCB NORDIC A/S.
ADRESSE: Arne Jacobsens Alle 15, 2300 København S.
Kommune:
København.
Kapital kr. 500.000,00.
Bestyrelse:
Luc René Benoît Vermeesch (formand), Jørgen Damsbo Andersen, Guido Irena Joannes Coleta Van Dingenen.
Direktion:
Jørgen Damsbo Andersen (adm.dir.).
Selskabet tegnes af bestyrelsens formand i forening med en direktør, to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Revision:
CVR-NR. 39746115 KPMG DANMARK A/S, Borups Alle 177, postboks 250, 2000 Frederiksberg.
Regnskabsår:
01.01 - 31.12.
Bestyrelse:
Udtrådt af bestyrelsen:
Hanne Jungdal Dannulat, den 10.05.2005, Mark Hardy, den 10.05.2005.
Vedtægter ændret:
13.04.2005.
Nyt navn:
UCB NORDICS ApS.
Bestyrelse:
Udtrådt af bestyrelsen:
Ingelise Saunders, den 24.01.2005, David Bruce Wildy, den 24.01.2005, John Derek Williams, den 24.01.2005.
Indtrådt i bestyrelsen:
Luc René Benoît Vermeesch (formand), den 24.01.2005, Hanne Jungdal Dannulat, den 24.01.2005, Guido Irena Joannes Coleta Van Dingenen, den 24.01.2005.
Ny adresse:
Lyngbyvej 20, 2100 København Ø.
Direktion:
Udtrådt af direktionen:
Indtrådt i direktionen:
Jørgen Damsbo Andersen (adm.dir.).
Vedtægter ændret:
09.09.2002.
Nyt navn:
CELLTECH NORDIC ApS.
Bestyrelse:
Indtrådt i bestyrelsen:
Mark Hardy, den 09.09.2002, Direktør Ingelise Saunders, den 09.09.2002, David Bruce Wildy, den 09.09.2002.
Direktion:
Udtrådt af direktionen:
Helle Freundlich Andersen, den 09.09.2002.
Indtrådt i direktionen:
Direktør Ingelise Saunders (adm. dir), den 09.09.2002.
Selskabet tegnes af to bestyrelsesmedlemmer i forening.
Revision:
Udtrådt af revisionen:
CVR-NR. 12523246 GRANT THORNTON, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 09.09.2002.
Indtrådt i revisionen:
CVR-NR. 39746115 KPMG DANMARK STATSAUTORISERET REVISIONSAKTIESELSKAB, Borups Alle 177, postboks 250, 2000 Frederiksberg, den 09.09.2002.
Stiftelsesdato:
05.07.2002.
Seneste vedtægtsdato:
05.07.2002.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 100,00.
Stifter:
CVR-NR. 10442486 KR 332 ApS, c/o Kromann Reumert, Sundkrogsgade 5, 2100 København Ø, den 05.07.2002.
Direktion:
Direktør Helle Freundlich Andersen, den 05.07.2002.
Selskabet tegnes af en direktør.
Revision:
CVR-NR. 12523246 GRANT THORNTON, STATSAUTORISERET REVISIONSAKTIESELSKAB, Stockholmsgade 45, 2100 København Ø, den 05.07.2002.
Første regnskabsår:
05.07.2002 - 31.12.2003.
Regnskabsår:
01.01 - 31.12.
1 registered in CVR.
P-number 1009204144Edvard Thomsens Vej 14, 2300 København S
No other current company drawn.
No other current company drawn.
No other current company drawn.